Visit Our HIV Medicines

Find Medical Information organized by product. Explore now

CONGRESS PRESENTATIONS

IAS 2023

the 12th IAS Conference on HIV Science

July 23-26, 2023, Brisbane, Australia & Virtual

Post-IAS Webinar with Discussion of Application to Clinical Practice

Please join our discussion on ViiV-sponsored data presented at the 2023 IAS Conference with panel discussion

ON DEMAND

Cabotegravir Treatment

Elliot E, et al. 

Similar inflammatory markers after switching to cabotegravir + rilpivirine long-acting vs. continuing bictegravir/emtricitabine/tenofovir alafenamide: data from the phase 3b SOLAR trial.
View Presentation
Download PDF
×

Elliot E, et al. 

Similar inflammatory markers after switching to cabotegravir + rilpivirine long-acting vs. continuing bictegravir/emtricitabine/tenofovir alafenamide: data from the phase 3b SOLAR trial.
Collapse ❯ Expand ❮
Download PDF

Eu B, et al.

Cabotegravir + rilpivirine long-acting outcomes by sex at birth, age, race, and body mass index: a subgroup analysis of the phase 3b SOLAR study.
View Presentation
Download PDF
×

Eu B, et al.

Cabotegravir + rilpivirine long-acting outcomes by sex at birth, age, race, and body mass index: a subgroup analysis of the phase 3b SOLAR study.
Collapse ❯ Expand ❮
Download PDF

Gutner CA, et al.

Optimizing the clinic flow process for integration of cabotegravir + rilpivirine long acting into routine care: findings from cabotegravir and rilpivirine implementation study in European locations (CARISEL).
View Presentation
Download PDF
×

Gutner CA, et al.

Optimizing the clinic flow process for integration of cabotegravir + rilpivirine long acting into routine care: findings from cabotegravir and rilpivirine implementation study in European locations (CARISEL).
Collapse ❯ Expand ❮
Download PDF

Scherzer J, et al.

Perceptions of cabotegravir + rilpivirine long-acting (CAB+RPV LA) from people living with HIV (PLHIV) in the CARLOS study.
View Presentation
Download PDF
×

Scherzer J, et al.

Perceptions of cabotegravir + rilpivirine long-acting (CAB+RPV LA) from people living with HIV (PLHIV) in the CARLOS study.
Collapse ❯ Expand ❮
Download PDF

Chounta V, et al.

Patient-reported outcomes after 12 months of maintenance therapy with long acting cabotegravir and rilpivirine compared with bictegravir emtricitabine tenofovir alafenamide in the phase 3b SOLAR study.
View Presentation
Download PDF
×

Chounta V, et al.

Patient-reported outcomes after 12 months of maintenance therapy with long acting cabotegravir and rilpivirine compared with bictegravir emtricitabine tenofovir alafenamide in the phase 3b SOLAR study.
Collapse ❯ Expand ❮
Download PDF

Dolutegravir-based Regimens

Patel P, et al.

Evaluation of incident hypertension and blood pressure changes among people living with HIV-1 (PLWH) receiving dolutegravir (DTG)-based regimens or comparator antiretroviral therapy (CAR) in randomized clinical trials through 96 weeks.
View Presentation
Download PDF
×

Patel P, et al.

Evaluation of incident hypertension and blood pressure changes among people living with HIV-1 (PLWH) receiving dolutegravir (DTG)-based regimens or comparator antiretroviral therapy (CAR) in randomized clinical trials through 96 weeks.
Collapse ❯ Expand ❮
Download PDF

Puthanakit T, et al.

Efficacy and safety of dolutegravir/lamivudine (DTG/3TC) in antiretroviral therapy (ART)-naive adolescents living with HIV-1: DANCE study Week 96 results.
View Presentation
Download PDF
×

Puthanakit T, et al.

Efficacy and safety of dolutegravir/lamivudine (DTG/3TC) in antiretroviral therapy (ART)-naive adolescents living with HIV-1: DANCE study Week 96 results.
Collapse ❯ Expand ❮
Download PDF

Smith DE, et al.

Switching to dolutegravir/lamivudine (DTG/3TC) is non-inferior to continuing tenofovir alafenamide (TAF)-based regimens at Week 196: TANGO subgroup analyses.
View Presentation
Download PDF
×

Smith DE, et al.

Switching to dolutegravir/lamivudine (DTG/3TC) is non-inferior to continuing tenofovir alafenamide (TAF)-based regimens at Week 196: TANGO subgroup analyses.
Collapse ❯ Expand ❮
Download PDF

Mussini C, et al.

Real-world observational study in Europe on the effectiveness and safety of two-drug regimens containing an integrase inhibitor and reverse transcriptase inhibitor (COMBINE-2): Week 96 stable switch population results.
View Presentation
Download PDF
×

Mussini C, et al.

Real-world observational study in Europe on the effectiveness and safety of two-drug regimens containing an integrase inhibitor and reverse transcriptase inhibitor (COMBINE-2): Week 96 stable switch population results.
Collapse ❯ Expand ❮
Download PDF

Rupasinghe D, et al.

Integrase strand inhibitors (INSTI) related changes in BMI and risk of diabetes.
View Presentation
Download PDF
×

Rupasinghe D, et al.

Integrase strand inhibitors (INSTI) related changes in BMI and risk of diabetes.
Title
Summary
Background
Objectives
Methods
Methods (continued)
Methods (continued)
Participant characteristics
Participant characteristics (continued)
Results
Results (continued)
Results (continued)
Overview
Limitations
Conclusion
Acknowledgements
Collapse ❯ Expand ❮
Download PDF

Byonanebye DM, et al.

Impact of INSTI and TAF-related BMI changes and risk on hypertension and dyslipidemia in RESPOND.
View Presentation
Download PDF
×

Byonanebye DM, et al.

Impact of INSTI and TAF-related BMI changes and risk on hypertension and dyslipidemia in RESPOND.
Title
Summary
Introduction
Methods
Participant eligibility
Incidence rate ratios of hyperteension
Incidence rate ratios of dyslipidemia
Conclusions
Acknowledgements
Collapse ❯ Expand ❮
Download PDF

Cabotegravir Prevention

Poteat R, et al.

Risk characteristics, risk perception, and long-acting PrEP awareness and interest among black and hispanic men: a national survey.
View Presentation
Download PDF
×

Poteat R, et al.

Risk characteristics, risk perception, and long-acting PrEP awareness and interest among black and hispanic men: a national survey.
Collapse ❯ Expand ❮
Download PDF

Elion RA, et al.

Real-world utilization and effectiveness of long-acting cabotegravir + rilpivirine in the United States: TRIO cohort study.
View Presentation
Download PDF
×

Elion RA, et al.

Real-world utilization and effectiveness of long-acting cabotegravir + rilpivirine in the United States: TRIO cohort study.
Collapse ❯ Expand ❮
Download PDF

Disease-Related Content

Choi JY, et al. 

Development of the HIV Care Continuum & Beyond Initiative: key focus areas to end HIV in the Asia-Pacific region.
View Presentation
Download PDF
×

Choi JY, et al. 

Development of the HIV Care Continuum & Beyond Initiative: key focus areas to end HIV in the Asia-Pacific region.
Full Poster
Title
Key takeaways
Methods
Results of the Modified Delphi Method
Focus Areas and Examples of Successful Interventions
Proposed Initiatives
Conclusion
Collapse ❯ Expand ❮
Download PDF

This content was acquired following an unsolicited medical information enquiry by a healthcare professional.  Always consult the product information for your country, before prescribing a ViiV medicine. ViiV does not recommend the use of our medicines outside the terms of their license.  In some cases, the scientific Information requested and downloaded may relate to the use of our medicine(s) outside of their license.

Connect With Us

Are you a US healthcare provider?

This web portal is intended as an educational resource for healthcare providers practicing in the United States. It may include information about products or uses that have not been approved by the US Food and Drug Administration.

If you are not a healthcare provider, please discuss any questions you have regarding your health or medicines with your doctor, pharmacist, or nurse.

Yes

No

Connect With Our Medical Experts

Find My ViiV MSL

Easily find the ViiV Medical Science Liaison (MSL) in your area.

Talk to a Medical Expert

Connect now with a live ViiV Medical Expert.

Request a Scientific Discussion

Submit a request for additional information from a ViiV Medical Expert.

Contact Us

Chat Live

Get immediate assistance from a ViiV Healthcare Professional.

Call 1‑888‑226‑8434

Weekdays from 8 AM to 6 PM ET
(5 AM – 3 PM PT)

Our Response to COVID-19

Report an Adverse Event

To report SUSPECTED ADVERSE REACTIONS, contact ViiV Healthcare at 1‑877‑844‑8872 or FDA at 1‑800‑332‑1088 or www.fda.gov/medwatch